TERN (Terns Pharmaceuticals) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Terns Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Terns Pharmaceuticals's Free Cash Flow for the three months ended in Sep. 2024 was $-16.46 Mil. Terns Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Terns Pharmaceuticals's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Terns Pharmaceuticals's current FCF Yield % is -13.14%.

The historical rank and industry rank for Terns Pharmaceuticals's FCF Margin % or its related term are showing as below:

During the past 6 years, the highest FCF Margin % of Terns Pharmaceuticals was -4216.70%. The lowest was -4216.70%. And the median was -4216.70%.

TERN's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -145.32
* Ranked among companies with meaningful FCF Margin % only.

Terns Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Terns Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Terns Pharmaceuticals FCF Margin % Chart

Terns Pharmaceuticals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-4,216.70

Terns Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Terns Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Terns Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Terns Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Terns Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Terns Pharmaceuticals's FCF Margin % falls into.

Terns Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Terns Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-67.442	/	0
	=	%

Terns Pharmaceuticals's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-16.455	/	0
	=	%

Terns Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Terns Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Terns Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Terns Pharmaceuticals Inc (NAS:TERN) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

430:Germany

Address

1065 East Hillsdale Boulevard, Suite 100, Foster, CA, USA, 94404

Website

https://www.ternspharma.com

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.

Executives

Hongbo Lu	director	C/O AVEDRO, INC., 201 JONES ROAD, WALTHAM MA 02451
Mark J. Vignola	officer: Chief Financial Officer	C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Jill M. Quigley	director	TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Seokho Bryan Yoon	officer: COO and General Counsel	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Vivo Opportunity Fund Holdings, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Senthil Vel Sundaram	director, officer: Chief Executive Officer	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Oriental Spring Venture Ltd	10 percent owner	UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Lav Biosciences Fund V, L.p.	10 percent owner	C/O ESTERA TRUST (CAYMAN) LIMITED, 75 FORT STREET, PO BOX 1350, GRAND CAYMAN E9 KY1-1108
Hopewell Resources Holdings Ltd	10 percent owner	UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Lav Aqua Ltd	10 percent owner	UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Iii Ltd	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629